Atossa Therapeutics, Inc. Common Stock ATOS
$4.70
-3.09%
at last close
Market Cap$41.77 million
P/E Ratio—
Div Yield—
Volume45.1K
52-Week Range
$3.76$19.35
Key Stats
- Today's Range
- $4.68 – $4.80
- 50-Day Range
- $4.59 – $6.28
- 52-Week Range
- $3.76 – $19.35
- Volume
- 45K shs
- Average Volume
- 49K shs
- Market Cap
- $41.77 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 1.37
- Price / Sales
- —
Short Interest
- Short Interest
- 18.01%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- —
- Net Income
- $-37,641,000
- Net Margin
- —
- Return on Equity
- -123.47%
- Debt-to-Equity
- —
About Atossa Therapeutics, Inc. Common Stock
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
Related Stocks
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.